Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

36.75 -0.63 (-1.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Harmony Biosciences's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock ↗
Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate ↗
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate 
Via Chartmill
News headline image
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. ↗
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
News headline image
Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Friday's pre-market session: top gainers and losers ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
In the world of growth stocks, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) shines as a value proposition. ↗
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
News headline image
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY): a strong growth stock preparing for the next leg up?. ↗
Based on a technical and fundamental analysis of NASDAQ:HRMY we can say: HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Expert Outlook: Harmony Biosciences Hldgs Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock which is not overvalued. ↗
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript ↗
HRMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder ↗
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025. 
Via Benzinga
News headline image
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug ↗
The agency rejected the drug in the application filing stage, which is earlier than usual. 
Via Investor's Business Daily
News headline image
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable. ↗
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
News headline image
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
NASDAQ:HRMY, a growth stock which is not overvalued. ↗
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.